stent

El Cilostazol disminuye la reestenosis de stents farmacológicos en lesiones de más de 40 mm.

T&iacute;tulo original: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Referencia: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. &nbsp; El Cilostazol, un inhibidor de la fosfodiesterasa III, asociado a aspirina y clopidogrel demostr&oacute; disminuir la reestenosis angiogr&aacute;fica en<a href="https://solaci.org/2013/10/07/el-cilostazol-disminuye-la-reestenosis-de-stents-farmacologicos-en-lesiones-de-mas-de-40-mm/" title="Read more" >...</a>

Stent liberador de everolimus en múltiples vasos con bajo SYNTAX score

T&iacute;tulo original: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Referencia: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. &nbsp; Los stents<a href="https://solaci.org/2013/09/24/stent-liberador-de-everolimus-en-multiples-vasos-con-bajo-syntax-score/" title="Read more" >...</a>

El ticagrelor reduce la trombosis intrastent en pacientes con síndromes coronarios agudos

T&iacute;tulo original: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial. Referencia: Steg PG et al. Circulation. 2013; Epub ahead of print &nbsp; El estudio PLATO randomiz&oacute; 18624 pacientes cursando un s&iacute;ndrome coronario agudo a recibir ticagrelor (180 mg de carga seguido de 90<a href="https://solaci.org/2013/09/12/el-ticagrelor-reduce-la-trombosis-intrastent-en-pacientes-con-sindromes-coronarios-agudos/" title="Read more" >...</a>

Stents farmacológicos de 2° generación para tronco de coronaria izquierda.

T&iacute;tulo original: Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study. Referencia: Julinda Mehilli et al. J Am Coll Cardiol, article in press. &nbsp; Las mejoras en la 2&deg; generaci&oacute;n de stents farmacol&oacute;gicos llevaron a una mayor eficacia y seguridad, sin embargo hab&iacute;a poca informaci&oacute;n sobre estas nuevas plataformas<a href="https://solaci.org/2013/08/29/stents-farmacologicos-de-2-generacion-para-tronco-de-coronaria-izquierda/" title="Read more" >...</a>

El Rivaroxaban disminuye la trombosis intrastent en pacientes con síndromes coronarios agudos

T&iacute;tulo original: Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. Referencia: C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. Hay pocos estudios contempor&aacute;neos que investigaron la utilidad de la anticoagulaci&oacute;n oral en pacientes con s&iacute;ndromes coronarios agudos y angioplastia coronaria. El Rivaroxaban es<a href="https://solaci.org/2013/08/23/el-rivaroxaban-disminuye-la-trombosis-intrastent-en-pacientes-con-sindromes-coronarios-agudos/" title="Read more" >...</a>

Stent liberador de zotarolimus en reestenosis intrastent

T&iacute;tulo original: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis. Referencia: Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. &nbsp; Estudios previos reportaron un revascularizaci&oacute;n de la lesi&oacute;n blanco (TLR) del 15% y del vaso blanco (TVR) del 22% al<a href="https://solaci.org/2013/08/16/stent-liberador-de-zotarolimus-en-reestenosis-intrastent/" title="Read more" >...</a>

Cobertura intimal de stents farmacológicos con overlap vs sin overlap

T&iacute;tulo original: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. Referencia: Juan Luis Guti&eacute;rrez-Chico et al. Am Heart J 2013;166:83-94.e3. El efecto de la superposici&oacute;n de stents farmacol&oacute;gicos (DES) sobre el proceso de cicatrizaci&oacute;n neointimal no est&aacute;<a href="https://solaci.org/2013/08/05/cobertura-intimal-de-stents-farmacologicos-con-overlap-vs-sin-overlap/" title="Read more" >...</a>

Denervación renal también para hipertensos resistentes moderados

T&iacute;tulo original: Renal denervation in moderate treatment resistant hypertension. Referencia: Christian Ott et al. J Am Coll Cardiol 2013. Article in press. Los estudios Symplicity HTN 1 y HTN 2 demostraron que la denervaci&oacute;n renal es aparentemente segura en pacientes con hipertensi&oacute;n resistente severa (&ge;160 mmHg a pesar de &ge; 3 drogas incluyendo un diur&eacute;tico).<a href="https://solaci.org/2013/07/24/denervacion-renal-tambien-para-hipertensos-resistentes-moderados/" title="Read more" >...</a>

Stent directo, sin utilidad clínica en pacientes electivos

T&iacute;tulo Original: The Independent Value of a Direct Stenting Strategy on Early and Late Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Referencia: Gabriel L. Sardi et al. Catheterization and Cardiovascular Interventions 81:949&ndash;956 (2013). &nbsp; El uso de stent directo (SD) (implante de stent sin pre dilataci&oacute;n) ha demostrado ser una estrategia segura, especialmente<a href="https://solaci.org/2013/06/18/stent-directo-sin-utilidad-clinica-en-pacientes-electivos/" title="Read more" >...</a>

Top